Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 10Terminated 3Recruiting 2Active not recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Androgen Antagonists 10darolutamide 6Magnetic Resonance Spectroscopy 6apalutamide 5Docetaxel 5enzalutamide 4Specimen Handling 4Radiotherapy 4Radiosurgery 4Abiraterone Acetate 4Electroacupuncture 3Brachytherapy 3pembrolizumab 2bicalutamide 2Standard of Care 2Resistance Training 2Radiation 2Prednisone 2Pluvicto 2Interviews as Topic 2Gonadotropin-Releasing Hormone 2Glutamate Carboxypeptidase II 2Bone Density 2Absorptiometry, Photon 2testosterone 17 beta-cypionate 1relugolix 1perflutren 1olaparib 1luprolide acetate gel depot 1fluciclovine F-18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Prostatic Neoplasms × fluciclovine F-18 × Clear all
NCT07569926 2026-05-06

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Blue Earth Diagnostics

Phase 4 Not yet recruiting
142 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡